Everyone complains about "translation barriers." Regulatory hurdles. Manufacturing challenges. Clinical trial costs. But has anyone noticed these "barriers" have been the same for decades while some therapeutics still reach patients quickly?
What if the real bottleneck isn't regulatory—it's that nobody's actually trying to solve the translation problem?
The Incentive Reality: BIOS research identifies "industrial hand-offs from academia, biomarker development, and early clinical trial regulations" as translation barriers. But notice what's missing: why these hand-offs fail.
Academic researchers get rewarded for publications, not patient outcomes. Pharmaceutical companies get rewarded for blockbuster drugs, not incremental patient access improvements. Regulators get rewarded for safety, not speed.
Nobody in the system is actually optimized for translation speed.
The Data Everyone Ignores: When translation urgency aligns with incentives, "barriers" disappear overnight. COVID vaccines: 11 months from sequence to patients. Not because we suspended regulations—because everyone in the system was suddenly aligned toward the same goal.
Ebola treatments, HIV drugs under expanded access, cancer immunotherapies under breakthrough designation—when incentives align, "regulatory barriers" become regulatory highways.
The Translation Psychology: Calling something a "barrier" implies it's someone else's problem to solve. "Regulatory barrier" = wait for regulators to change. "Manufacturing barrier" = wait for better technology. "Clinical trial barrier" = wai